User profiles for Devis Benfaremo

Devis Benfaremo

Dipartimento di Scienze Cliniche e Molecolari, Universitą Politecnica delle Marche
Verified email at staff.univpm.it
Cited by 1032

[HTML][HTML] Diagnosis and management of leukocytoclastic vasculitis

P Fraticelli, D Benfaremo, A Gabrielli - Internal and emergency medicine, 2021 - Springer
Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small
vessel vasculitis (SVV), that can be found in various types of vasculitis affecting the skin and …

Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature

D Benfaremo, L Manfredi, MM Luchetti… - Current drug …, 2018 - ingentaconnect.com
Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that
have been associated with a number of immune-related Adverse Events (AEs), including …

[HTML][HTML] Systemic sclerosis: from pathophysiology to novel therapeutic approaches

D Benfaremo, S Svegliati, C Paolini, S Agarbati… - Biomedicines, 2022 - mdpi.com
Systemic sclerosis (SSc) is a systemic, immune-mediated chronic disorder characterized by
small vessel alterations and progressive fibrosis of the skin and internal organs. The …

Abnormal liver function tests predict transfer to intensive care unit and death in COVID‐19

S Piano, A Dalbeni, E Vettore, D Benfaremo… - Liver …, 2020 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has emerged as a
relevant threat for humans worldwide. Abnormality in liver function tests (LFTs) has been …

[HTML][HTML] Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

M Mattioli, D Benfaremo, M Mancini, L Mucci… - Journal of thrombosis …, 2021 - Springer
Coagulopathy represents one of the most important determinants of morbidity and mortality
in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or …

Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic

MM Luchetti, D Benfaremo, A Campanati… - Clinical …, 2018 - Springer
Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune arthritis, occurring in patients
with psoriasis (Pso), that may affect the whole musculoskeletal system but also nails, eye, …

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: Data from an Italian multicentre study

…, B Vigone, B Ruaro, A Stanziola, D Benfaremo… - RMD open, 2023 - rmdopen.bmj.com
Introduction Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial
lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life …

[HTML][HTML] PDGF/PDGFR: a possible molecular target in scleroderma fibrosis

C Paolini, S Agarbati, D Benfaremo… - International Journal of …, 2022 - mdpi.com
Systemic sclerosis (SSc) is a clinically heterogeneous disorder of the connective tissue
characterized by vascular alterations, immune/inflammatory manifestations, and organ fibrosis. …

[HTML][HTML] Current take on systemic sclerosis patients' vaccination recommendations

…, L Delfino, M Triggiani, C Cardamone, D Benfaremo… - Vaccines, 2021 - mdpi.com
Systemic sclerosis (SSc) is a rare autoimmune inflammatory rheumatic disease. The
prevalence of SSc ranges from 7 to 700 cases per million worldwide. Due to multiple organ …

The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with …

M Di Carlo, MM Luchetti, D Benfaremo, E Di Donato… - Clinical …, 2018 - Springer
To develop and to test in a preliminary way a new self-administered screening tool, called
DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire, in patients …